Bone Therapeutics Hires CFO
Bone Therapeutics SA has hired a new chief financial officer.
Wim Goemaere has more than 25 years of international business experience, the majority of which he has spent within the biotechnology arena. He joins Gosselies, Belgium-based Bone Therapeutics from Devgen, a Belgium-based multinational agro-biotech company, where he worked as CFO for five years. He was instrumental in ensuring the endorsement of Devgen in the financial markets and in the recent takeover of Devgen by Syngenta for 403 million euros, according to Bone Therapeutics executives. He also played a vital role in Devgen’s business expansion in Asia.
Prior to Devgen, Goemaere was CFO of the Flanders Institute for Biotechnology, where he helped develop the organization from a startup to one of the world’s leading research bodies in life sciences.
“I am pleased to be joining Bone Therapeutics at such a crucial time in the company’s development," Goemaere said. "With a Phase III trial ongoing for the company’s lead product Preob and a pipeline of clinical stage bone disease cell therapy products, Bone Therapeutics is at a transformational point in its development. I look forward to working closely with the management team to ensure the company’s continuing success.”
Goemaere began his career at BP, holding various roles with increasing responsibility before leaving the company to pursue his career in biotech. He holds a degree in applied economics from KU Leuven (in Belgium).
“We are delighted that Wim is joining Bone Therapeutics," CEOEnrico Bastianelli said. "His extensive experience of both the financial and biopharmaceutical sectors will be invaluable to the company as we progress to the next stage of our development.”
Bone Therapeutics is an international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases. Its lead product is designed to treat osteonecrosis and non-union fractures. Bone Therapeutics also is developing an allogeneic bone cell therapy product, Allob, which is expected to enter clinical trials later this year, and MXB, a combined cell-matrix product for the treatment of large bone defects, currently in preclinical development.